Colorado remote patient monitoring firm, BioIntelliSense’s chest-mounted BioButton designed to monitor a range of vital signals can cut hospital times, enhance early detection and increase positive outcomes.
The study, published in the Journal of Clinical Medicine, examined nearly 12,000 hospitalised patients finding that the company’s remote monitoring device can cut a typical patient’s hospital time down from 3.07 days to 2.75 days over 12 months.
Additionally, the trial found that on average, the first vital sign notifications were triggered 14.8 hours before a deterioration event, giving patients and clinicians much more of a head start on serious adverse events (AEs).
The study, which was conducted over 15 months in the medical-surgical units of two US hospitals, utilised the company’s multi-parameter continuous monitoring device which is placed on the chest of a patient when they enter the hospital.
Dubbed the BioButton, the device continuously measures core vital signs including heart rate at rest, respiratory rate at rest, skin temperature, and activity levels, collecting up to 1,440 measurements per patient per day.
James Mault, the founder of BioIntelliSense, said: “The study underscores the value of implementing continuous monitoring wearable technology, combined with algorithmic-based data analytics, in general care areas of the hospital to automate vital sign collection and to deliver clinical intelligence for actionable decision making. The BioButton system's ability to deliver timely and accurate notifications enables earlier detection of clinical deterioration and plays a critical role in proactively managing a patient’s health outcomes.”
The study additionally found that compared to traditional hand-charted vital signs, the system saw 114 cases receiving new or changed physician’s orders due to BioButton notifications. All the patients in medical-surgical units enrolled in the study were monitored from a centralised location by a single nurse during weekdays on the day shift. Research by GlobalData found that the market for remote patient monitoring sat at a value of around $600m at the end of 2023, with that value estimated to rise to $760m by 2030.
GlobalData is the parent company of Clinical Trials Arena.
Elsewhere in the field of remote monitoring technology, the UK’s National Institute for Health and Care Excellence (Nice) has published guidelines calling for the use of a remote heart monitoring pathway in people with cardiac implantable electronic devices, such as pacemakers, living with heart failure. Elsewhere, analysts at GlobalData have identified a growth in innovative diabetes management solutions in Singapore.
